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Background
•

Approximately 41-50% of ovarian carcinomas are estimated to exhibit homologous
recombination deficiency (HRD)

•

Germline and somatic tumor tissue testing (TTT) for mutations in BRCA1/2 and assessment of
HRD informs prognosis and treatment decisions

•

NCCN guidelines (V1.2022) recommend germline and somatic TTT and assessment of HRD for
all women with invasive EOC

•

Data on the frequency of HRD is based primarily on analysis of EOC patients treated at
academic medical centers and/or enrolled in clinical trials and may not be representative of a
larger population of women in a community setting

Homologous Recombination Repair (HRR) is a pathway
for repair of double strand breaks in DNA

In Homologous Recombination Deficiency (HRD),
DNA repair is inhibited which results in genomic
instability

HRD is a useful predictor of treatment response to
PARP inhibitor in patients with mBRCA1/mBRCA2

How do you test for HRD?
Germline mutation screening of genes related to HRR

- Germline mutational testing (GMT)
Somatic mutation screening of genes related to HRR

-Somatic Tumor Tissue Testing (TTT)
Evaluation of genomic instability secondary to HRD via a genomic instability score (GI) or loss of heterozygosity
(LOH)

GI score results from combined analysis of three
different biomarkers

Objective
To identify the frequency of HRD based on mutations in homologous recombination repair (HRR) genes,
genomic instability (GI), and loss of heterozygosity (LOH) scores in a large community-based cohort of EOC
patients (study population as described previously)
o Additional data collected
•HRR genes separate from BRCA1/2 include: ATM, BARD1,
BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2,
PPP2R1A, PPP2R2A, RAD51B, RAD51C, RAD51D,
RAD54L
•GI as measured by Myriad myChoice test, LOH as
measured primarily by Caris and Foundation tests
o Data analysis
•Descriptive statistics were tabulated
•Chi-squared analysis was performed to compare
frequencies
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Conclusions
• Somatic TTT identified evidence of HRD in 130 of 507 (26%) patients tested
• Pathogenic somatic TTT mutations in HRR genes were identified in 87 (17%) patients including
BRCA1 (n=47), BRCA2 (n=23), ATM (n=8), CHEK2 (n=4), PALB2 (n=2), RAD51b (n=1), CDK12 (n=1)
and BRIP1 (n=1)
• Molecular alterations were identified in tumors of all stages, suggesting that broad based somatic TTT
may be of value
• A large fraction of patients with HRD may not be receiving indicated PARPi therapy

